Shanghai HeartCare Medical Technology Management
Management criteria checks 4/4
Shanghai HeartCare Medical Technology's CEO is Guohui Wang, appointed in Jun 2016, has a tenure of 9.75 years. total yearly compensation is CN¥1.65M, comprised of 59.2% salary and 40.8% bonuses, including company stock and options. directly owns 23.47% of the company’s shares, worth HK$373.25M. The average tenure of the management team and the board of directors is 5.3 years and 5.3 years respectively.
Key information
Guohui Wang
Chief executive officer
CN¥1.7m
Total compensation
| CEO salary percentage | 59.24% |
| CEO tenure | 9.8yrs |
| CEO ownership | 23.5% |
| Management average tenure | 5.3yrs |
| Board average tenure | 5.3yrs |
Recent management updates
Recent updates
Revenues Not Telling The Story For Shanghai HeartCare Medical Technology Corporation Limited (HKG:6609) After Shares Rise 32%
Jan 05
Some Shanghai HeartCare Medical Technology Corporation Limited (HKG:6609) Shareholders Look For Exit As Shares Take 29% Pounding
Nov 04Investors Shouldn't Be Too Comfortable With Shanghai HeartCare Medical Technology's (HKG:6609) Earnings
Sep 30A Piece Of The Puzzle Missing From Shanghai HeartCare Medical Technology Corporation Limited's (HKG:6609) 27% Share Price Climb
Aug 18Shanghai HeartCare Medical Technology Corporation Limited's (HKG:6609) Shares Leap 29% Yet They're Still Not Telling The Full Story
Jul 03We Think Shareholders Are Less Likely To Approve A Pay Rise For Shanghai HeartCare Medical Technology Corporation Limited's (HKG:6609) CEO For Now
May 19Shanghai HeartCare Medical Technology Corporation Limited's (HKG:6609) 32% Share Price Surge Not Quite Adding Up
Feb 10Even With A 42% Surge, Cautious Investors Are Not Rewarding Shanghai HeartCare Medical Technology Corporation Limited's (HKG:6609) Performance Completely
Sep 27Some Shareholders Feeling Restless Over Shanghai HeartCare Medical Technology Corporation Limited's (HKG:6609) P/S Ratio
Aug 01We're Not Very Worried About Shanghai HeartCare Medical Technology's (HKG:6609) Cash Burn Rate
Jan 23Shanghai HeartCare Medical Technology Corporation Limited (HKG:6609) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely
Aug 30Companies Like Shanghai HeartCare Medical Technology (HKG:6609) Are In A Position To Invest In Growth
Aug 09Companies Like Shanghai HeartCare Medical Technology (HKG:6609) Are In A Position To Invest In Growth
May 07We're Hopeful That Shanghai HeartCare Medical Technology (HKG:6609) Will Use Its Cash Wisely
Nov 29CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | CN¥42m |
| Mar 31 2025 | n/a | n/a | CN¥14m |
| Dec 31 2024 | CN¥2m | CN¥978k | -CN¥14m |
| Sep 30 2024 | n/a | n/a | -CN¥29m |
| Jun 30 2024 | n/a | n/a | -CN¥45m |
| Mar 31 2024 | n/a | n/a | -CN¥69m |
| Dec 31 2023 | CN¥1m | CN¥799k | -CN¥94m |
| Sep 30 2023 | n/a | n/a | -CN¥141m |
| Jun 30 2023 | n/a | n/a | -CN¥188m |
| Mar 31 2023 | n/a | n/a | -CN¥194m |
| Dec 31 2022 | CN¥1m | CN¥1m | -CN¥200m |
| Sep 30 2022 | n/a | n/a | -CN¥185m |
| Jun 30 2022 | n/a | n/a | -CN¥169m |
| Mar 31 2022 | n/a | n/a | -CN¥188m |
| Dec 31 2021 | CN¥21m | CN¥1m | -CN¥194m |
| Sep 30 2021 | n/a | n/a | -CN¥242m |
| Jun 30 2021 | n/a | n/a | -CN¥290m |
| Mar 31 2021 | n/a | n/a | -CN¥244m |
| Dec 31 2020 | CN¥82m | CN¥771k | -CN¥214m |
Compensation vs Market: Guohui's total compensation ($USD239.08K) is about average for companies of similar size in the Hong Kong market ($USD326.67K).
Compensation vs Earnings: Guohui's compensation has been consistent with company performance over the past year.
CEO
Guohui Wang (46 yo)
Mr. Guohui Wang is the Chief Executive Officer and Director of Shanghai HeartCare Medical Technology Corporation Limited since June 2016 and serves as its Chairman since November 23, 2020. He served as the...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 9.8yrs | CN¥1.65m | 23.47% HK$ 375.9m | |
| Executive Director | 5.3yrs | CN¥1.07m | 3.68% HK$ 59.0m | |
| Deputy GM & Executive Director | 5.3yrs | CN¥2.11m | no data | |
| CFO & Joint Company Secretary | 5.3yrs | no data | no data | |
| Joint Company Secretary | 4yrs | no data | no data |
Experienced Management: 6609's management team is seasoned and experienced (5.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 9.8yrs | CN¥1.65m | 23.47% HK$ 375.9m | |
| Executive Director | 5.3yrs | CN¥1.07m | 3.68% HK$ 59.0m | |
| Deputy GM & Executive Director | 3.8yrs | CN¥2.11m | no data | |
| Independent Non-Executive Director | 5.3yrs | CN¥237.00k | no data | |
| Non-Executive Director | 2.3yrs | no data | no data | |
| Non-Executive Director | 5.3yrs | no data | 2.07% HK$ 33.1m | |
| Independent Non-Executive Director | 5.3yrs | CN¥201.00k | no data | |
| Independent Non-Executive Director | 5.2yrs | CN¥200.00k | no data | |
| Non-Executive Director | 3.3yrs | CN¥120.00k | no data |
Experienced Board: 6609's board of directors are considered experienced (5.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/08 02:33 |
| End of Day Share Price | 2026/03/06 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shanghai HeartCare Medical Technology Corporation Limited is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jin Zhang | China International Capital Corporation Limited |
| null null | China International Capital Corporation Limited |
| Yuan Gao | China International Capital Corporation Limited |